

Research

Open Access

Severe falciparum malaria in young children of the Kassena-Nankana district of northern Ghana

Abraham R Oduro*¹, Kwadwo A Koram², William Rogers³, Frank Atuguba¹, Patrick Ansah¹, Thomas Anyorigiya¹, Akosua Ansah¹, Francis Anto¹, Nathan Mensah¹, Abraham Hodgson¹ and Francis Nkrumah²

Address: ¹Navrongo Health Research Centre, P.O. Box 114, Navrongo, Ghana, ²Noguchi Memorial Institute for Medical Research, UG, Box 25, Legon, Accra, Ghana and ³Naval Medical Research Centre, Malaria Program, Silver Spring, Maryland, USA

Email: Abraham R Oduro* - aroduro@yahoo.com; Kwadwo A Koram - kkoram@noguchi.mimcom.net; William Rogers - brogers@noguchi.mimcom.net; Frank Atuguba - fatugubah@navrongo.mimcom.net; Patrick Ansah - panasah@navrongo.mimcom.net; Thomas Anyorigiya - tanyorigiya@navrongo.mimcom.net; Akosua Ansah - aansah@navrongo.mimcom.net; Francis Anto - fanto@navrongo.mimcom.net; Nathan Mensah - nmensah@navrongo.mimcom.net; Abraham Hodgson - ahodgson@navrongo.mimcom.net; Francis Nkrumah - fnkrumah@noguchi.mimcom.net

* Corresponding author

Published: 27 July 2007

Received: 12 January 2007

Malaria Journal 2007, **6**:96 doi:10.1186/1475-2875-6-96

Accepted: 27 July 2007

This article is available from: <http://www.malariajournal.com/content/6/1/96>

© 2007 Oduro et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Study design: Severe falciparum malaria in children was studied as part of the characterization of the Kassena-Nankana District Ghana for future malaria vaccine trials. Children aged 6–59 months with diagnosis suggestive of acute disease were characterized using the standard WHO definition for severe malaria.

Results: Of the total children screened, 45.2% (868/1921) satisfied the criteria for severe malaria. Estimated incidence of severe malaria was 3.4% (range: 0.4–8.3%) cases per year. The disease incidence was seasonal: 560 cases per year, of which 70.4% occurred during the wet season (June–October). The main manifestations were severe anaemia (36.5%); prolonged or multiple convulsions (21.6%); respiratory distress (24.4%) and cerebral malaria (5.4%). Others were hyperpyrexia (11.1%); hyperparasitaemia (18.5%); hyperlactaemia (33.4%); and hypoglycaemia (3.2%). The frequency of severe anaemia was 39.8% in children of six to 24 months of age and 25.9% in children of 25–60 months of age. More children (8.7%) in the 25–60 months age group had cerebral malaria compared with 4.4% in the 6–24 months age group. The overall case fatality ratio was 3.5%. Cerebral malaria and hyperlactataemia were the significant risk factors associated with death. Severe anaemia, though a major presentation, was not significantly associated with risk of death.

Conclusion: Severe malaria is a frequent and seasonal childhood disease in northern Ghana and maybe an adequate endpoint for future malaria vaccine trials.

Background

Globally, an estimated 350–500 million clinical malaria episodes occur annually; most of these are caused by infection with *Plasmodium falciparum* with more than one million deaths each year. About 60% of the clinical episodes and more than 80% of the deaths occur in young children in Africa, south of the Sahara, where malaria accounts for 25–35% of all outpatients visits, 20–45% of hospital admissions and 15–35% of hospital deaths [1,2]. Despite the introduction in recent years of more rational antimalarial regimens and the increasing use of the most rapidly parasitocidal artemisinin derivatives [3,4], the malaria risk and mortality has not seen significant reductions yet [5,6]. Studies on factors associated with increased risk of developing severe malaria and death, may provide additional understanding of the course of severe malaria, and, eventually, lead to improved case management, and the development of drugs and vaccines for malaria.

Moreover, this requires the establishment of appropriate case definitions and meaningful trial endpoints for future testing in endemic sites [7]. Several studies, at various sites in Africa, have attempted to delineate the epidemiology of clinical malaria, and the data have shown significant variability across various transmission zones [8-12]. There is, therefore, a need for more site-specific data in order to appreciate the complete clinical and epidemiological picture needed for efficient testing of candidate malaria vaccines and other control tools in different endemic sites. Young children with severe malaria enrolled in order to study the course of severe malaria in the Kassena-Nankana district of northern Ghana, a site being characterized for future malaria vaccine trials.

Methods

Study setting

The study was carried out in the Navrongo War Memorial Hospital (NWMH) located in the Kassena-Nankana District (KND) of northern Ghana. The KND lies in the sahelian savannah and covers about 1,674 square kilometres of land with a population of approximately 143,000 under continuous demographic surveillance [13]. The area is characterized by two distinct seasons; a rainy season from June to October and a hot dry season from November to May. Annual rainfall averages 850 mm and means daily temperature ranges from 20°C to 40°C. Malaria transmission is perennial with distinct seasonal patterns. The peak malaria transmission coincides with the period of major rains while the dry season has low rates of malaria infection [14]. Infection is attributed mostly to *P. falciparum* with *Anopheles funestus* and *Anopheles gambiae* as the principal vectors [15]. The estimated annual entomological inoculation rates [15], parasite

prevalence [14], malaria attack rates [16] and antimalaria efficacy rates [17] have been well studied.

Study design and participants

All children between six and 59 months of age, who were admitted at the NWMH with diagnosis suggestive of acute disease, from August to December 2002 and from May 2003 to April 2004, were evaluated for inclusion in the study. Criteria for diagnosis and enrolment included the standard WHO definition for severe malaria [18,19]. Those who satisfied the selection criteria including residence in the KND and whose parents voluntarily gave informed consent were enrolled. Parents were interviewed about the presenting symptoms and study physicians documented findings of clinical examination including weight and vital signs. In addition, the course of illness, including daily vital signs and peripheral blood parasitaemia, were documented for each study child from the time of enrolment to the time of exit from the hospital. Patients were seen daily while on admission and on day 7, 10 and 14 following discharge from the hospital. Those who were alive on day 14 after admission were considered to have survived the acute severe malaria episode. Parents of surviving children were interviewed at home on days 7, 10 and 14 to determine whether their child or ward remained in good health. Participants completed the study by satisfying all study entry requirements and providing all specimens and interviews as provided for by the protocol. This report describes the clinical and laboratory characteristics as well as the prognostic indicators for children admitted with severe malaria.

Laboratory procedures

At enrolment, peripheral malaria blood smears, full blood count and blood lactate were done for all participants. While on admission, blood smears were taken for daily parasitological examinations until two consecutive smears were aparasitaemic, and on days 7 and 14 from the day of enrolment. Thick and thin blood films were made, thin film fixed with methanol and both thin and thick film stained with 10% Giemsa and examined for malaria parasites. Parasite density was measured as the number of parasites per 200 leucocytes on a thick film and converted into parasites per microlitre of blood based on the participants total white cell count obtained at enrolment. Ten percent of both positive and negative slides were randomly selected and read by an independent microscopist as a quality control check. Two hundred high power fields of the thick films were examined at 1,000× magnification before assigning a negative result. Whole blood specimens were analysed for full blood count using automated ABX Micros 60-OT haematology analyser; serum creatinine, blood glucose and transaminases levels were determined using Micro lab 200, and blood lactate using YSI lactate analyzer.

Clinical management

Children were treated using a uniform protocol based on standard recommendations[19] consisting of parenteral quinine at 20 mg/kg loading dose followed by 10 mg/kg maintenance dose every 12 hours until the patient was able to swallow, at which point she or he was switched to an oral dose of 10 mg/kg every eight hours to complete a seven day course of treatment. In addition to the specific treatment for *P. falciparum* infection, children received supportive therapy in terms of haemotransfusion for severe anaemia, intravenous glucose for hypoglycaemia and intravenous fluid for severe dehydration. Paracetamol suppositories were administered for pyrexia, diazepam for seizures, antibiotics for bacterial infections, and nasal oxygen for respiratory distress as per standard local practice.

Approvals

Ethical approval for this study was obtained from the following ethical committees: the Ghana Health Service, the Navrongo Health Research Centre, the Noguchi Memorial Institute for Medical Research and the United States Naval Medical Research Center.

Data and statistical analysis

All study data were captured on a structured case report form bearing subject demographic and identification numbers. All forms were reviewed before being double entered onto a computer. Statistical analyses were carried out with Epi Info 6.04 (ENSP-Epiconcept-InVS, Corp.) and Stata statistical software (version 7.0, Stata Corporation, College Station, Texas, USA). Continuous and normal distributed data were compared by two-tailed student's t-test and proportions compared with χ^2 tests with Yates' correction or Fisher's exact test. Basic statistics were calculated for the baseline characteristics- sex, age group, weight, fever, parasitaemia, presenting symptoms, malaria prevention practices and area of residence. Point estimates using proportions and means, and 95% confidence intervals were computed for the clinical and laboratory features. Significant differences were tested using confidence intervals of the difference or odds ratio and the corresponding (95%) confidence intervals and p-values. A p-value of ≤ 0.05 was considered statistically significant.

Results

Baseline characteristics

Out of the total of 1,921 children screened, 73.1% (1405/1921) had a positive parasitaemia and, of these, 61.8% (868/1405) satisfied the criteria for severe *falciparum* malaria. About 56% (490/868) of the total enrollees were males and majority of 76% [661/868] aging below 24 months of age (Figure 1). The average age and weight were respectively 18.9 months (range: 6–59) and 8.9 kilograms [95%CI 8.7, 9.1]. At baseline, the mean haemoglobin and geometric mean parasite density were 6.1 g/dl [range 1.8–

13.7] and 26903-parasites/ μ l [95%CI 22026, 32860] respectively. The proportion with fever (axillary temperature $\geq 37.5^\circ\text{C}$), thrombocytopenia and leucocytosis were 77.3% (671/868), 52.1% (452/868) and 47.7% (414/868), respectively. Other enrolment symptoms were vomiting (66.6%), cough (60.7%), shaking chills (57.5%), breathing difficulty (57.4%), lethargy (52.4%), diarrhoea (43.0%), convulsion (39.1%), and inability to eat 38.2%. Reported insecticide-treated bed net (ITN) use and prior malarial chemotherapy were 58.8% (510/868) and 49.5% (430/868) respectively.

Major clinical and prognostic features

Cerebral malaria

In all, 47 (5.4%) of the children had cerebral malaria (Blantyre coma score < 3), the frequency of cerebral malaria in the 25–60 months old was 8.7% [95% CI 5.2,13.4] compared to 4.4% [95% CI 2.9, 6.2] in 6–24 months olds. Proportions of boys and girls with cerebral malaria were similar (5% (23/490) vs. 6% (24/378). Fewer children with cerebral malaria had severe anaemia compared to those without cerebral malaria (28%(13/47) vs. 37% (302/816). Again a higher proportion of children with cerebral malaria had higher respiratory distress than those without (70.2% vs. 21.3%). The mean of haemoglobin, serum lactate and blood glucose among cerebral malaria patients were 7.0 g/dl, 8.5 mmol/l, and 6.2 mmol/l, respectively. The total case fatality ratio among children with cerebral malaria was 29.8% (14/47).

Severe anaemia

This was the most frequent manifestation, 36.5% (315/863), and was more prevalent in males than females [40.2% vs. 31.6%], in 6–24 month olds than 25–60 olds




Figure 1
Age-specific distribution of severe malaria and anaemia in the northern Ghana. Children aged 6–59 months with severe malaria by WHO criteria (white) and severe anaemia (black).

[39.8 vs. 25.9], Figure 1, and in those not using ITNs than those using ITNs [41.9% vs.32.7%]. The overlap of severe anaemia with cerebral malaria and respiratory distress were 4.1% (13/315) and 38.7% (122/315) respectively (Figure 2). About 87% (274/315) of children with severe anaemia at enrolment received a blood transfusion. The frequencies of severe anaemia in children residing in the irrigated and non-irrigated areas were 29.9(38/127) and 37.6(277/736) respectively. The total case fatality ratio among children with severe anaemia was 3.5%(11/315) but for those who had no other associated severe malaria pathology, total recovery was achieved (Figure 2).

Respiratory distress

About 24% (212/868) of the participants presented with respiratory distress. Children with respiratory distress were likely to be younger (mean age, 18 months), and had higher geometric mean parasite density (22,026 parasites/microlitre)(Table 1). Again respiratory distress was significantly associated with severe anaemia (OR 3.3 95%CI 2.3, 4.6) and hyperlactataemia (OR 2.3 95%CI 1.5,3.2). The case fatality ratio of respiratory distress was 8.5% [95% 5.1,13.1]. The ratio was significantly increased to 23.8% and 33.3% if the respiratory distress overlapped with cerebral malaria or cerebral malaria plus severe anaemia respectively (Figure 2).

Other severe malaria manifestations at enrolment were multiple or prolonged convulsions 21.6% (187/864), hyperlactataemia 33.4% (249/746), hyperparasitaemia 18.5% (161/868) and hypoglycaemia 3.2% (24/761).

Factors associated with malaria death

The overall study case fatality ratio was 3.5 (30/868). The ratio was similar in males and females (3.3% vs. 3.7%) and in 6–24 and 25–59 month's olds (3.3 vs. 3.9%). Their baseline presentations were: cerebral malaria 46.7% (14/30), severe anaemia 36.7% (11/30), respiratory distress 60%(18/30) and hyperlactataemia 61.5(16/26). Bivariate




Figure 2
Venn diagram of proportions, overlap and mortality of severe malaria major clinical subgroups. Total number of major clinical subgroups in parenthesis and, mortality is given as percentage.

analysis (Table 2) showed that cerebral malaria, hypoglycaemia, respiratory distress and hyperlactaemia were the risk factors associated with most deaths, but logistic regression analysis showed that only cerebral malaria OR= 12.9(95% CI 4.1,40.8) and hyperlactataemia OR = 1.2 (95%CI 1.1, 1.3) were risk factors associated with falciparum malaria death.

Incidence of severe malaria

To estimate severe malaria incidence in the population, a mid year population of children 6–59 months old in the district from the Navrongo demographic surveillance database and the total cases from May 2003 to April 2004 were used. In all, there were 16,298 children (aged 6 to 59 months) and 560 severe malaria cases giving an overall incidence of 0.034 cases per year. The incidence was highest in the age group, 6–11 months and lowest in the 48–59 month old (Table 3).

Table 1: Characteristics of the major clinical subgroups.

Parameters	Cerebral Malaria (n = 47)	Severe Anaemia (n = 315)	Respiratory Distress (n = 212)
Males, n (%)	23(48.9)	202(61.8)	117(55.2)
6–24 months, n (%) mean age	21.6 (13.1)	16.5(10.0)	17.9(11.3)
Mean haemoglobin, g/dl (SD)	7.0(2.6)	3.8(0.8)	5.2(2.3)
Mean blood lactate, mmol/L(SD)	8.5(5.7)	5.8(4.1)	6.6(4.9)
*GMPD, parasites/μL	15223	15361	22026
Mean blood glucose, mmol/L (SD)	6.2(3.6)	5.0(1.8)	5.1(2.1)
Hypoglycaemia, n (%)	6(12.8)	8(2.5)	18(8.5)
Hyperlactataemia, n (%)	34(72.3)	142(45.1)	101(47.6)
Hyperparasitaemia, n(%)	8(17.0)	34(10.8)	33(15.6)
Hyper pyrexia, n (%)	1(2.1)	12(3.8)	28(13.2)

* GMPD = geometric mean parasite density

Table 2: Prognostics indicators at the time of enrolment

Outcome	Prevalence,n(%)	Fatalities, n(%)	OR	χ^2	95% CI	P-value
Cerebral malaria	47 (5.4)	14(29.8)	21.3	103.3	8.7,50.7	0.000
Severe anaemia	315 (36.5)	11(3.5)	1.02	0.02	0.45,2.28	0.88
Respiratory distress	212 (24.4)	18 (8.5)	4.9	20.7	2.1,11.3	0.000
Hyperlactataemia	290 (33.4)	19 (6.6)	3.6	20.7	1.6,8.6	0.000
Hypoglycaemia	33 (3.8)	4(12.1)	4.3	7.7	1.0,13.5	0.005

Seasonal variation

Of the 560 cases of severe malaria enrolled during the one year period [May 2003 to April 2004], 70.4% (394/560) were enrolled in June-October (the high transmission season) and 29.4%(166/560) in November-May (low transmission season). The highest number of cases, 127 (22.7%) were enrolled in September and the lowest, 6 (1.1%) in April (Figure 3). Though more cases of severe anaemia (72%) occurred during the high transmission season, the proportions of severe anaemia in the high and low seasons were similar (35.5% vs. 33.1% p-value > 0.05). About 71% (22/31) of cerebral malaria cases occurred in the wet season compared to 29% (9/31) in the dry season. The geometric mean parasite density in the high season was 37,876 parasites/ μ l [95%CI 31,069/46,174] compared to 21,473-parasites/ μ l [95%CI 15,564/29,624] in the low season. The prevalence of hyperparasitaemia was also greater in the high transmission season than in the low season (22.1% versus 7.4%, p-value < 0.001). The case fatality ratios during the high and low seasons were 4.2% (7/166) and 1.8% (7/394), respectively.

Discussion

As part of malaria characterization studies in northern Ghana in preparation for malaria vaccine trials severe malaria among young children was studied. The results showed that significant population and numbers of severe *P. falciparum* malaria exist in the Kassena-Nankana District of northern Ghana that may represent an adequate vaccine trial endpoint. Severe malaria, as a vaccine trial endpoint offers several advantages over other endpoints that could be used in future malaria vaccine efficacy trials

Table 3: Age-specific incidence of severe malaria in the KND (2003–2004)

Age group (Months)	Mid year population (% of total)	Number of cases (% of total)	Estimated incidence of severe malaria.
6–11	1632 (10.0)	136 (24.2)	0.083
12–23	3474 (21.3)	262 (46.8)	0.075
24–35	3536 (21.7)	105 (18.8)	0.030
36–47	3816 (23.4)	41 (07.3)	0.011
48–59	3840 (23.6)	16 (02.9)	0.004
Total	16298 (100)	560 (100)	0.034

[20,21]. Even though mortality impact is the most important public health measure of any vaccine efficacy, it represents a smaller proportion of all disease burdens and will, thus, require large sample size in future trials [22]. Also, in many malaria endemic countries, assignment of causes of deaths may present sensitivity and specificity problems that may lead to misclassification and reduction of the statistical power of any trial with mortality as an endpoint[23]. On the other hand, it is difficult to define and differentiate mild malaria and infection as endpoints from many of the other common febrile illnesses in most endemic areas [24,25]. Again the comparative ease of using the established case definitions of severe malaria [18] and the fact that most children diagnosed as having the disease have worse prognoses than those with mild disease makes severe malaria a better trial endpoint. Well-defined severe malaria, therefore, bridges the gap of being common enough for a reduction to be measurable and as




Figure 3
Seasonal prevalence of severe malaria and anaemia in the Kassena-Nankana district of Ghana. WHO criteria of severe malaria (white) and severe anaemia (black) by month of the year.

important as possible to predict malaria-associated mortality in endemic sites [21]. For instance, in the recent study in Mozambique, RTSS/AS02A vaccine showed a significant protection against severe malaria [26].

The current study showed that over a period of fifteen months, 868 severe cases were recruited, with most of the cases (76%) being children between 6–24 months old, with a significant decreasing trend towards increasing age (Figure 1). As in other settings the predominant manifestation was severe malarial anaemia. Other clinical and laboratory manifestations were also consistent with what have earlier been reported in other endemic settings [9–12]. Using the total number of cases of severe malaria in one year and the mid year population of children at risk in the study area, the annual incidence of severe malaria was estimated to be 3.4% (95% CI 3.1,3.7): ranging from 0.4% in 48–59 months old to 8.3% in 6–12 months olds (Table 3). This is significantly higher than the 2.3% reported in a similar setting in another part of West Africa [21], even though this represent only hospital cases instead of census as in that study [21]. This suggesting that this finding may even be an underestimation, as some children might have died at home during the period since almost all cases of untreated severe and complicated malaria are fatal.

The overall case fatality ratio in this study was 3.5%; this was similar by gender (3.3% vs. 3.7%) and by the age groups (3.3% vs. 3.9%). The independent prognostic indicators were cerebral malaria and hyperlactataemia confirming the fact that in severe malaria, neurological involvement and metabolic dysfunction are the factors that are most associated with poor outcome [9,27,28]. Severe anaemia, though the most frequent presenting feature, was a poor predictor of death [29,30], perhaps because most severe malaria anaemia children received timely blood transfusion. Despite this, severe anaemia will be an important vaccine trial endpoint because of its frequency, especially in children and because of the ease with which it can be measured with certainty in field situations.

Further significant seasonal variation of severe malaria was recorded over the period. The highest prevalence occurred in the months of July to December (during the rainy season). The observed pattern points to the fact that increase in vector breeding following the raining season is responsible for the upsurge in the malarial cases and supports an earlier transmission studies [15]. In malaria endemic areas, majority of malaria death and morbidity occur during the peak transmission seasons. As such, the intermittent preventive treatment approaches to malaria control during this intense period [31] could impact on reducing disease burden. Such preventive measures could

reduce the risk of severe malaria and subsequently minimize its effect as a vaccine trial endpoint. For instance the results showed that ITNs usage was high; patients not using ITNs had higher incidence of severe anaemia and cerebral malaria compared to those using ITNs. These considerations need to be factored in when estimating sample size for future vaccine studies.

Conclusion

Major conclusions can be drawn from this study. First, severe malaria in the area occurs frequently in the first 30 months of life, the predominant feature being severe anaemia. Most of the severe malaria occurs in the high transmission and short period, which suggest that the area can effectively support intervention studies including vaccine trials in the prevailing short, but intensive, transmission season.

Authors' contributions

AO, KK, WR, FN: conception and design, and data acquisition, analysis and interpretation. Manuscript drafting and revision for the intellectual content.

FA, FA, AT: conception and design, and acquisition and interpretation of data.

PA, AA, NM, AH: acquisition and interpretation of data, and manuscript preparation.

Acknowledgements

Our special gratitude goes to all our study participants and their parents, members of the Kassena-Nankana community and the severe malaria team for their cooperation and understanding. We are also grateful to the staff of Navrongo War Memorial Hospital, Navrongo Health Research Center, Noguchi Memorial Institute for Medical Research and US Naval Medical Research Center Malaria Program for the administrative, logistical and technical support. Our special thanks go to Drs Lee Hall, Abdollah Naficy and Tonu Wali of NIAID for their guidance and technical support. The views expressed here do not purport to reflect those of the Ghanaian Ministry of Health or those of the National Institute of Allergy and Infectious Diseases (NIAID). This work was made possible by National Institute of Allergy and Infectious Diseases (NIAID) contract NO1 A195363 (Malaria: Clinical Research and Trial Preparation Sites) to the Noguchi Memorial Institute for Medical Research (NMIMR) and subcontracted to the Navrongo Health Research Centre.

References

1. World Health Organization: **Roll Back Malaria**. *World Malaria Report 2005*.
2. Bremen JG: **The ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burden**. *Am J Trop Med Hyg* 2001, **64**(1-2 Suppl):1-11.
3. WHO: *Antimalarial Drug Combination Therapy. Report of a WHO Technical Consultation. WHO/CDS/RBM/2001/35. [Position of WHO's Roll Back Malaria Department on malaria treatment policy]* 2001.
4. Majori G: **Combined antimalarial therapy using artemisinin**. *Parasitologia* 2004, **46**:85-87.
5. Breman JG, Alilio MS, Mills A: **Conquering the intolerable burden of malaria: what's new, what's needed**. *Am J Trop Med Hyg* 2004, **71**:1-15.

6. Hay SI, Guerra CA, Tatem AJ, Noor AM, Snow RW: **The global distribution and population at risk of malaria: past, present, and future.** *Lancet* 2004, **4(6)**:327-336.
7. Ballou WR, Arevalo-Herrera M, Carucci D, Richie TL, Carradin G, Diggs C, Druilhe P, Gierring BK, Saul A, Heppner DG, Kester KF, Lanar DE, Lyon J, Hill AV, Pan W, Cohen JD: **Update on the clinical development of candidate malaria vaccines.** *Am J Trop Med Hyg* 2004, **71**:239-247.
8. Bojang KA, van Hensbroek MB, Palmer A, Banya WA, Jaffar S, Greenwood BM: **Predictors of mortality in Gambian children with severe malaria anaemia.** *Ann Trop Paediatr* 1997, **17**:355-359.
9. Marsh K, Forste D, Waruiru C, Mwangi I, Winstanley M, Marsh V, Newton C, Winstanley P, Warn P, Peshu N, Pasvol G, Snow R: **Indicators of life-threatening malaria in African children.** *N Engl J Med* 1995, **332**:1399-1404.
10. Schellenberg D, Menendez C, Kahigwa E, Font F, Galindo C, Acosta C, Schellenberg JA, Aponte JJ, Kimario J, Urassa H, Mshinda H, Tanner M, Alonso P: **African children with malaria in an area of intense *Plasmodium falciparum* transmission: features on admission to the hospital and risk factors for death.** *Am J Trop Med Hyg* 1999, **61**:431-438.
11. Vaahtera M, Kulmala T, Maleta K, Cullinan T, Salin ML, Ashorn P: **Epidemiology and predictors of infant morbidity in rural Malawi.** *Paediatr Perinat Epidemiol* 2001, **14**:363-371.
12. Dzeing-Ella P, Obiang PC, Tchoua R, Planche T, Mboza B, Mbounja M, Muller-Roemer U, Jarvis J, Kendjo E, Ngou-Milama E, Krensner PG, Krishna S, Kombila M: **Severe *falciparum* malaria in Gabonese children: clinical and laboratory features.** *Malar J* 2005, **4**:1.
13. Binka FN, Ngom P, Phillips JF, Adazu K, Macleod BB: **Assessing population dynamics in a rural African society: The Navrongo demographic surveillance system.** *J Biosocial Sci* 1999, **31**:375-391.
14. Koram KA, Owusu-Agyei S, Fryauff DJ, Anto F, Atuguba F, Hodgson A, Hoffman SL, Nkrumah FK: **Seasonal profiles of malaria infection, anaemia, and bednet use among age groups and communities in northern Ghana.** *Trop Med Int Health* 2003, **8**:793-802.
15. Appawu M, Owusu-Agyei S, Dadzie S, Asoala V, Anto F, Koram K, Rogers W, Nkrumah F, Hoffman SL, Frayauff DJ: **Malaria transmission dynamics at a site in northern Ghana.** *Trop Med Int Health* 2004, **9**:164-170.
16. Baird JK, Owusu-Agyei S, Utz GC, Koram K, Barcus MJ, Jones TR, Frayauff DJ, Binka FN, Hoffman SL, Nkrumah F: **Seasonal malaria attack rates in infants and young children in northern Ghana.** *Am J Trop Med Hyg* 2002, **66**:280-286.
17. Oduro AR, Anyorigiya T, Hodgson A, Ansah P, Anto F, Ansah NA, Atuguba F, Mumuni G, Amankwa J: **A randomized comparative study of chloroquine, amodiaquine and sulfadoxine-pyrimethamine for the treatment of acute malaria in Ghana.** *Trop Med Int Health* 2005, **10**:279-284.
18. World Health Organization: **Severe and complicated malaria.** *Trans R Soc Trop Med Hyg* 1990, **84**:1-65.
19. World Health Organization: *Management of severe malaria: a practical handbook* Geneva; 2000.
20. World Health Organization: *Guidelines for the evaluation of plasmodium falciparum vaccines in populations exposed to natural infection*, Geneva 1997. TDR/MAL/VAC/97
21. Lyke KE, Dicko A, Kone A, Coulibaly D, Guindo A, Cissoko Y, Traore K, Plowe CV, Doumbo OK: **Incidence of severe *Plasmodium falciparum* malaria as a primary endpoint for vaccine efficacy trials in Bandiagara, Mali.** *Vaccine* 2004, **22**:3169-3174.
22. D'Alessandro U, Olaleye BO, McGuire W, Langerock P, Bennett S, Aikins MK, Thomson MC, Cham MK, Cham BA, Greenwood BM: **Mortality and morbidity from malaria in Gambian children after introduction of an impregnated bednet programme.** *Lancet* 1995, **345**:479-483.
23. Jaffar S, Leach A, Smith PG, Cutts F, Greenwood B: **Effects of misclassification of causes of death on the power of a trial to assess the efficacy of a pneumococcal conjugate vaccine in The Gambia.** *Int J Epidemiol* 2003, **32**:430-436.
24. Tarimo DS, Minjas JN, Byeberg IC: **Malaria diagnosis and treatment under the strategy of the integrated management of childhood illness (IMCI): relevance of laboratory support from the rapid immunochromatographic tests of ICT Malaria P.f/P.v and OptiMal.** *Ann Trop Med Parasitol* 2001, **95**:437-444.
25. Perkins BA, Zucker JR, Otieno J, Jafari HS, Paxton L, Redd SC, Nahlen , Schwartz B, Oloo AJ, Olango C, Gove S, Campbell CC: **Evaluation of an algorithm for integrated management of childhood illness in an area of Kenya with high malaria transmission.** *Bull World Health Organ* 1997, **75**:33-42.
26. Alonso PI, Sacarlal J, Aponte JJ, Leach A, Macete F, Milman J, Mandomando I, Spiessen B, Guinovart C, Espasa M, Bassat Q: **Efficacy of the RTS,S/AS02A vaccine against *Plasmodium falciparum* infection and disease in young African children: randomised controlled trial.** *Lancet* 2004, **364**:1411-1420.
27. Planche T, Krishna S: **The relevance of malaria pathophysiology to strategies of clinical management.** *Curr Opin Infect Dis* 2005, **18**:369-375.
28. Maitland K, Bejon P, Newton CR: **Malaria.** *Curr Opin Infect Dis* 2003, **16**:389-395.
29. Mockenhaupt FP, Ehrhardt S, Burkhardt J, Bosomtwe SY, Laryea S, Anemana SD, Otchwemah RN, Cramer JP, Dietz F, Gelleret S, Bienzle U: **Manifestation and outcome of severe malaria in children in northern Ghana.** *Am J Trop Med Hyg* 2004, **71**:167-172.
30. Planche T, Agbeyenga T, Bedu-Addo G, Ansong D, Owusu-Ofori A, Micah F, Anakwa C, Asafo-Agyei E, Hutson A, Stacpoole PW, Krishna S: **A prospective comparison of malaria with other severe disease in African children: Prognosis and optimization of management.** *Clin Inf Dis* 2003, **37**:890-897.
31. Chandramohan D, Owusu-Agyei S, Carneiro I, Awine T, Amponsa-Achiano K, Mensah N, Jaffar S, Baiden R, Hodgson A, Binka F, Greenwood B: **Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana.** *BMJ* 2005, **331**:727-733.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

